Kirkland Assists Kelun-Biotech on its HK$2.7 Billion H-Share Placing

Kirkland & Ellis represented the placing agents, including Goldman Sachs, Citigroup and J.P.Morgan, in connection with the H-share placing (the H-Share Placing) of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (Kelun-Biotech, HKEx: 6990). The H-Share Placing was announced on July 8, 2026 and completed on July 10, 2026.

The net proceeds from the H-Share Placing (after deducting all fees, costs and expenses incurred by Kelun-Biotech) amounted to approximately HKD 2.723 billion, which will be used for the research and development, clinical trials, registration filings, manufacturing and commercialization of its products; to enhance its internal research and development technology capabilities, strengthen external collaboration, and expand its product pipeline portfolio; and to replenish working capital and for general corporate purposes.

The Kirkland team included capital markets lawyers Mengyu Lu, George Zheng and Yuchen Han.